- Home
- AEF vs TSHA Comparison
AEF vs TSHA Comparison
Compare AEF & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEF
- TSHA
- Stock Information
- Founded
- AEF 1989
- TSHA 2019
- Country
- AEF United States
- TSHA United States
- Employees
- AEF N/A
- TSHA N/A
- Industry
- AEF Finance/Investors Services
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- AEF Finance
- TSHA Health Care
- Exchange
- AEF Nasdaq
- TSHA Nasdaq
- Market Cap
- AEF 237.8M
- TSHA 262.4M
- IPO Year
- AEF N/A
- TSHA 2020
- Fundamental
- Price
- AEF $4.84
- TSHA $1.24
- Analyst Decision
- AEF
- TSHA Strong Buy
- Analyst Count
- AEF 0
- TSHA 8
- Target Price
- AEF N/A
- TSHA $6.63
- AVG Volume (30 Days)
- AEF 92.5K
- TSHA 2.4M
- Earning Date
- AEF 01-01-0001
- TSHA 05-13-2025
- Dividend Yield
- AEF 7.13%
- TSHA N/A
- EPS Growth
- AEF N/A
- TSHA N/A
- EPS
- AEF 0.57
- TSHA N/A
- Revenue
- AEF N/A
- TSHA $8,333,000.00
- Revenue This Year
- AEF N/A
- TSHA N/A
- Revenue Next Year
- AEF N/A
- TSHA N/A
- P/E Ratio
- AEF $8.86
- TSHA N/A
- Revenue Growth
- AEF N/A
- TSHA N/A
- 52 Week Low
- AEF $4.40
- TSHA $1.05
- 52 Week High
- AEF $5.53
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- AEF 46.04
- TSHA 40.35
- Support Level
- AEF $4.80
- TSHA $1.05
- Resistance Level
- AEF $4.78
- TSHA $1.36
- Average True Range (ATR)
- AEF 0.15
- TSHA 0.17
- MACD
- AEF 0.02
- TSHA -0.01
- Stochastic Oscillator
- AEF 65.08
- TSHA 25.68
About AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. It invests in the public equity and fixed income markets of Chile. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, Private Equity, telecommunication services, healthcare, real estate and industrials.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.